A phase 1/2 trial of AMT-116 in advanced solid tumours, run by Multitude Therapeutics Inc., now recruiting.
AMT-116 in Patients with Solid Tumors is a phase 1/2 interventional study registered as NCT06782334 by Multitude Therapeutics Inc., with 144 participants planned, started 2024-05-07 and due to reach its primary completion in 2026-06-30. Interventions recorded: AMT-116.
Shares Multitude Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.